Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer.
Cancer Treat Rev
; 126: 102724, 2024 May.
Article
in En
| MEDLINE
| ID: mdl-38636443
ABSTRACT
Non-small cell lung cancer (NSCLC) stages I-III are predominantly treated with surgery and combination immunotherapy and chemotherapy. A majority of these studies excluded patients with EGFR and ALK alterations. There are several completed and ongoing trials evaluating neoadjuvant treatment with EGFR-TKI monotherapy, combination therapy with chemotherapy, and combination therapy with immunotherapy. Here, we review completed clinical trials and discuss current ongoing trials' potential benefits, challenges, and future directions in the field.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Neoadjuvant Therapy
/
Protein Kinase Inhibitors
/
ErbB Receptors
/
Lung Neoplasms
Limits:
Humans
Language:
En
Journal:
Cancer Treat Rev
Year:
2024
Document type:
Article
Affiliation country:
Estados Unidos